Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing incidence of head and neck cancer
3.2.1.2 Growing geriatric population base
3.2.1.3 Rising investment in R&D to develop new drugs
3.2.1.4 Supportive reimbursement policies & rising awareness about disease
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of treatment
3.2.2.2 Side effects and safety concerns
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Therapy Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Chemotherapy
5.3 Immunotherapy
5.4 Targeted therapy
5.5 Other therapies
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Injectable
6.3 Oral
6.4 Other routes of administration
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospital pharmacy
7.3 Retail & specialty pharmacy
7.4 Online pharmacy
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 AbbVie Inc.
9.2 Amgen Inc.
9.3 AstraZeneca plc
9.4 Bristol-Myers Squibb Company (BMS)
9.5 C.H. Boehringer Sohn AG & Co. KG
9.6 Clinigen Group plc.
9.7 Coherus BioSciences
9.8 Cumberland Pharmaceuticals, Inc.
9.9 Eli Lilly and Company
9.10 F. Hoffmann-La Roche Ltd.
9.11 GSK plc
9.12 Merck & Co., Inc.
9.13 Sanofi S.A.
9.14 Takeda Pharmaceutical Company Limited
9.15 Teva Pharmaceutical Industries Ltd.
